Minimal effect of ketoconazole on cyclosporine (SangCyA™) oral absorption and first-pass metabolism in rats: Evidence of a significant vehicle effect on SangCyA absorption

Biopharmaceutics and Drug Disposition

Volumn 23, Issue 2, 2002, Pages 53-57

  Wong, Susan ^a   Wong, Harrison T ^a   Wacher, Vincent J ^a,b  

^a AvMax Inc   (United States)

^b Ontogen Corporation   (United States)

Author keywords

Absorption; Cyclosporine; Ketoconazole; Rats; Vehicle

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DRUG VEHICLE; KETOCONAZOLE; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUTION; FIRST PASS EFFECT; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; RAT; RAT STRAIN;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; KETOCONAZOLE; MALE; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET; VEHICLES;

EID: 0036092030     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.295     Document Type: Article

References (15)

1. Cyclosporin clinical pharmacokinetics
2. A new microemulsion formulation of cyclosporin: Pharmacokinetic and clinical features
3. Comparison of two cyclosporine formulations in healthy volunteers: Bioequivalence of the new Sang-35 formulation and Neoral
4. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
5. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants
6. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine
7. Effect of ketoconazole on cyclosporine dose in healthy dogs
8. Peppermint oil enhances cyclosporine oral bioavailability in rats. Comparison to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and ketoconazole
9. Species differences in the hepatic and intestinal metabolism of cyclosporine
10. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
11. From the Food and Drug Administration: Nationwide recall of SangCya oral solution
12. Oral cyclosporin formulations
13. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats
14. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes
15. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells